Biohaven
✦ Quant Ownership Signal how this is computed
- Total institutional ownership rose 0.3 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 94.32% +0.29pp
- Institutions
- 343
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| John Childs | Independent Director | 6.54% |
| Vladimir Coric | Chairperson & CEO | 2.55% |
| Gregory Bailey | Independent Director | 1.34% |
| Warren Volles | General Counsel & Chief Legal Officer | 0.16% |
| Matthew Buten | Chief Financial Officer | 0.13% |
| Kimberly Gentile | Senior Vice President of Clinical Operations | 0.07% |
| George Clark | Vice President | 0.06% |
| Bruce Car | Chief Innovation Officer | 0.04% |
| Julia Gregory | Independent Director | 0.02% |
| Kishan Mehta | Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +1,000 | $12.34 |
| 2026-08-05 | Infinitum Asset Management, LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-07-08 | Warren Volles | General Counsel & Chief Legal Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-27 | John Childs | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Julia Gregory | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Robert Hugin | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Gregory Bailey | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Michael Heffernan | Lead Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Irina Antonijevic | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Kishan Mehta | Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-03-16 | Kishan Mehta | Director | Other Acquisition | +17,342 | -- |
| 2026-03-16 | Kishan Mehta | Director | Other Disposition | -17,342 | -- |
| 2026-02-26 | Matthew Buten | Chief Financial Officer | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | Vladimir Coric | Chairperson & CEO | Other Derivative Acquisition | +550,000 | $11.52 |
| 2026-02-26 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | Bruce Car | Chief Innovation Officer | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | George Clark | Vice President | Other Derivative Acquisition | +50,000 | $11.52 |
| 2026-01-04 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Sale | -2,594 | $9.93 |
| 2026-01-04 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Retained | +1,656 | -- |
| 2026-01-04 | Vladimir Coric | Chairperson & CEO | Derivative Exercise and Sale | -7,430 | $9.93 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:17 · For reference only, not investment advice and not tailored to your situation.
Biohaven discussion 0 comments